FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2023130746> ?p ?o ?g. }

• W2023130746 endingPage "655" @default.
• W2023130746 startingPage "645" @default.
• W2023130746 abstract "There are few long-term clinical and magnetic resonance imaging (MRI) data on patients treated with interferon-beta (IFN-beta) for relapsing-remitting multiple sclerosis (RRMS). The aim of this study was to provide clinical and MRI data on 68 patients with RRMS treated over a 6-year period and to investigate whether a baseline MRI predicts their long-term clinical and MRI outcome. Six MRI scans were performed monthly before treatment and a further 13 scans were performed during treatment with IFN-beta, the last of which 6 years after commencement of treatment. The relapse rate, disability as measured by the Expanded Disability Status Scale (EDSS), and MRI parameters, including Gd-enhancing lesion load (Gd-LL), T2 hyperintense lesion load (T2-LL) T1 hypointense lesion load (T1-LL) and supratentorial brain volume (SBV) were measured throughout the study. The mean annual relapse rate over the 6 years was 0.52 (SD 0.67), which is significantly lower (68.6%) than the mean annual relapse rate of 1.6 observed during the 2-year period before the commencement of treatment (P < 0.01). The median EDSS score increased from 2 to 2.5, remaining stable in 60% of the patients. From the baseline scan to the final scan, there was a median increase of 7% in the T2-LL and 23.9% in the T1-LL, whilst SBV decreased by 2.7%. The increase in the EDSS over the course of the study was significantly correlated with a reduction in brain volume (r = 0.46, P = 0.001). Greater brain damage at baseline, as measured by both T2-LL and T1-LL, was significantly associated with an increase in disability over the 6 years (r = 0.44, P = 0.0009; r = 0.50, P = 0.0007, respectively). This study shows a sustained effect of IFN-beta on the relapse rate, which is lower than during the 2 years before treatment commencement. More than half the patients showed an improvement or stabilization in the EDSS score. The increment in disability was correlated with the development of brain atrophy but not with increases in lesion burden. Finally, the finding that the extent of lesion burden at the baseline was a strong predictor of increasing disability suggests that IFN-beta treatment might have a moderate effect in modifying the multiple sclerosis (MS) disease course over 6 years unless preventive treatment is started early." @default.
• W2023130746 created "2016-06-24" @default.
• W2023130746 creator A5019474973 @default.
• W2023130746 creator A5024757100 @default.
• W2023130746 creator A5026026352 @default.
• W2023130746 creator A5028275814 @default.
• W2023130746 creator A5033485090 @default.
• W2023130746 creator A5044053651 @default.
• W2023130746 creator A5046385801 @default.
• W2023130746 creator A5050367507 @default.
• W2023130746 creator A5064714256 @default.
• W2023130746 creator A5083385630 @default.
• W2023130746 creator A5090359104 @default.
• W2023130746 date "2002-11-01" @default.
• W2023130746 modified "2023-10-16" @default.
• W2023130746 title "A 6-year clinical and MRI follow-up study of patients with relapsing-remitting multiple sclerosis treated with Interferon-beta" @default.
• W2023130746 cites W1966515383 @default.
• W2023130746 cites W1972094162 @default.
• W2023130746 cites W1973286946 @default.
• W2023130746 cites W1982787660 @default.
• W2023130746 cites W1992383729 @default.
• W2023130746 cites W2023030135 @default.
• W2023130746 cites W2023180387 @default.
• W2023130746 cites W2023385152 @default.
• W2023130746 cites W2026402754 @default.
• W2023130746 cites W2036909473 @default.
• W2023130746 cites W2057350647 @default.
• W2023130746 cites W2071743510 @default.
• W2023130746 cites W2080337955 @default.
• W2023130746 cites W2084940546 @default.
• W2023130746 cites W2099467824 @default.
• W2023130746 cites W2100650001 @default.
• W2023130746 cites W2105477343 @default.
• W2023130746 cites W2110386728 @default.
• W2023130746 cites W2112165124 @default.
• W2023130746 cites W2116064638 @default.
• W2023130746 cites W2122454460 @default.
• W2023130746 cites W2125422382 @default.
• W2023130746 cites W2129794982 @default.
• W2023130746 cites W2132228594 @default.
• W2023130746 cites W2139367012 @default.
• W2023130746 cites W2140885259 @default.
• W2023130746 cites W2146057830 @default.
• W2023130746 cites W2156826748 @default.
• W2023130746 cites W2165547142 @default.
• W2023130746 cites W2167819459 @default.
• W2023130746 cites W2169098250 @default.
• W2023130746 cites W2170360850 @default.
• W2023130746 cites W2509277703 @default.
• W2023130746 cites W4210548604 @default.
• W2023130746 cites W4234254101 @default.
• W2023130746 cites W4244801936 @default.
• W2023130746 doi "https://doi.org/10.1046/j.1468-1331.2002.00476.x" @default.
• W2023130746 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12453081" @default.
• W2023130746 hasPublicationYear "2002" @default.
• W2023130746 type Work @default.
• W2023130746 sameAs 2023130746 @default.
• W2023130746 citedByCount "65" @default.
• W2023130746 countsByYear W20231307462012 @default.
• W2023130746 countsByYear W20231307462013 @default.
• W2023130746 countsByYear W20231307462014 @default.
• W2023130746 countsByYear W20231307462015 @default.
• W2023130746 countsByYear W20231307462016 @default.
• W2023130746 countsByYear W20231307462017 @default.
• W2023130746 crossrefType "journal-article" @default.
• W2023130746 hasAuthorship W2023130746A5019474973 @default.
• W2023130746 hasAuthorship W2023130746A5024757100 @default.
• W2023130746 hasAuthorship W2023130746A5026026352 @default.
• W2023130746 hasAuthorship W2023130746A5028275814 @default.
• W2023130746 hasAuthorship W2023130746A5033485090 @default.
• W2023130746 hasAuthorship W2023130746A5044053651 @default.
• W2023130746 hasAuthorship W2023130746A5046385801 @default.
• W2023130746 hasAuthorship W2023130746A5050367507 @default.
• W2023130746 hasAuthorship W2023130746A5064714256 @default.
• W2023130746 hasAuthorship W2023130746A5083385630 @default.
• W2023130746 hasAuthorship W2023130746A5090359104 @default.
• W2023130746 hasConcept C118552586 @default.
• W2023130746 hasConcept C126322002 @default.
• W2023130746 hasConcept C126838900 @default.
• W2023130746 hasConcept C141071460 @default.
• W2023130746 hasConcept C143409427 @default.
• W2023130746 hasConcept C187382586 @default.
• W2023130746 hasConcept C2780640218 @default.
• W2023130746 hasConcept C2780892749 @default.
• W2023130746 hasConcept C2781156865 @default.
• W2023130746 hasConcept C2910198813 @default.
• W2023130746 hasConcept C2989005 @default.
• W2023130746 hasConcept C2991897378 @default.
• W2023130746 hasConcept C2994247566 @default.
• W2023130746 hasConcept C3020694758 @default.
• W2023130746 hasConcept C71924100 @default.
• W2023130746 hasConceptScore W2023130746C118552586 @default.
• W2023130746 hasConceptScore W2023130746C126322002 @default.
• W2023130746 hasConceptScore W2023130746C126838900 @default.
• W2023130746 hasConceptScore W2023130746C141071460 @default.
• W2023130746 hasConceptScore W2023130746C143409427 @default.
• W2023130746 hasConceptScore W2023130746C187382586 @default.
• W2023130746 hasConceptScore W2023130746C2780640218 @default.

• next